Novavax and European Commission Finalize Advance Purchase Agreement for up to 200 million doses of COVID-19 Vaccine
— Agreement for 100 million doses with option for additional 100 million doses through 2023 — Expected to be the first protein subunit COVID-19 vaccine available in the European Union Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it has reached an agreement with the European Commission (EC) […]